246 related articles for article (PubMed ID: 29020329)
1. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Harris DR; Price G; Baker A; Meyer WA; Wilson CM; Hazra R; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2018 Jan; 66(2):220-228. PubMed ID: 29020329
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Havens PL; Stephensen CB; Hazra R; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2012 Apr; 54(7):1013-25. PubMed ID: 22267714
[TBL] [Abstract][Full Text] [Related]
3. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
Pornpaisalsakul K; Songtaweesin WN; Tepmongkol S; Wongharn P; Kawichai S; Suponsilchai V; Anugulruengkitt S; Puthanakit T;
J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Havens PL; Long D; Schuster GU; Gordon CM; Price G; Wilson CM; Kapogiannis BG; Mulligan K; Stephensen CB;
Antivir Ther; 2018; 23(7):623-628. PubMed ID: 30260797
[TBL] [Abstract][Full Text] [Related]
5. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
6. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Havens PL; Hazra R; Stephensen CB; Kiser JJ; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Gordon CM; Mulligan K;
Antivir Ther; 2014; 19(6):613-8. PubMed ID: 24535626
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
[TBL] [Abstract][Full Text] [Related]
9. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Taiwo BO; Chan ES; Fichtenbaum CJ; Ribaudo H; Tsibris A; Klingman KL; Eron JJ; Berzins B; Robertson K; Landay A; Ofotokun I; Brown T;
Clin Infect Dis; 2015 Oct; 61(7):1179-88. PubMed ID: 26060295
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
11. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.
Overton ET; Chan ES; Brown TT; Tebas P; McComsey GA; Melbourne KM; Napoli A; Hardin WR; Ribaudo HJ; Yin MT
Ann Intern Med; 2015 Jun; 162(12):815-24. PubMed ID: 26075752
[TBL] [Abstract][Full Text] [Related]
15. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
Mirembe BG; Kelly CW; Mgodi N; Greenspan S; Dai JY; Mayo A; Piper J; Akello CA; Kiweewa FM; Magure T; Nakabiito C; Marrazzo JM; Chirenje ZM; Riddler SA;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):287-94. PubMed ID: 26866954
[TBL] [Abstract][Full Text] [Related]
16. Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?
Mela Q; Ruggiero V; Montaldo L; Pisano U; Matta L; Maria Pasetto C; Onali S; Cacace E; Carta MG; Barca L; Chessa L
HIV Clin Trials; 2018 Oct; 19(5):188-196. PubMed ID: 30445888
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Della Negra M; De Carvalho AP; De Aquino MZ; Pinto JA; Da Silva MT; Andreatta KN; Graham B; Liu YP; Quirk EK
Pediatr Infect Dis J; 2015 Apr; 34(4):398-405. PubMed ID: 25599284
[TBL] [Abstract][Full Text] [Related]
19. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
[TBL] [Abstract][Full Text] [Related]
20. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
